BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Can-Fite BioPharma Ltd. 

Reinhold Cohn House
P.O.Box: 4060
Tel Aviv      Israel
Phone: 03-7109330 Fax: 03-5606405


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Drug Discovery





 Company News
Can-Fite BioPharma (CFBI)'s CEO Pnina Fishman Interviewed By The Life Sciences Report 3/5/2015 10:31:18 AM
Can-Fite BioPharma (CFBI) Receives Notice Of Allowance In U.S. For Psoriasis Patent 2/17/2015 8:53:50 AM
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015 7:26:38 AM
Can-Fite BioPharma (CFBI)'s CF602 Demonstrates Efficacy In Treatment Of Sexual Dysfunction In Preclinical Studies 1/27/2015 7:29:41 AM
Can-Fite BioPharma (CFBI) Announces Upcoming 2015 Clinical Milestones For Its Pipeline Of Drugs In 4 Indications 1/6/2015 7:29:30 AM
Can-Fite BioPharma (CFBI) Completes The Design Of The Rheumatoid Arthritis Phase 3 Study Of Its Lead Drug Candidate Cf101 12/30/2014 7:23:58 AM
Can-Fite BioPharma (CFBI) Doses First Patient In Global Phase 2 Liver Cancer Trial For CF102 12/22/2014 7:51:41 AM
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014 7:42:18 AM
Can-Fite BioPharma (CFBI) To Initiate The Development Program Of Its Next Generation Drug Cf602 12/9/2014 7:36:12 AM
Can-Fite BioPharma (CFBI) Announces $8 Million At-The-Market Registered Direct Offering 12/2/2014 2:28:46 PM
12345678910...